Login to Your Account



MAP Gets Boost on Positive Phase III Migraine Study

By Catherine Hollingsworth


Wednesday, May 27, 2009
Shares in MAP Pharmaceuticals Inc. spiked 185.7 percent Tuesday on the news that its Phase III migraine study of Levadex hit all four primary objectives. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription